ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, T.
Right arrow Articles by Heng, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, T.
Right arrow Articles by Heng, B. C.
Annals of Clinical & Laboratory Science 35:227-229 (2005)
© 2005 Association of Clinical Scientists

Intracellular Antibodies (Intrabodies) versus RNA Interference for Therapeutic Applications

Tong Cao and Boon Chin Heng
Stem Cell Laboratory, Faculty of Dentistry, National University of Singapore, Singapore

Address correspondence to Dr. Boon Chin Heng, Stem Cell Laboratory, Faculty of Dentistry, National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074; tel 656 874 4630; fax 65 6774 5701; e-mail denhenga{at}nus.edu.sg.

Currently there are two technology platforms for the ablation of protein function: (a) RNAi-mediated gene-silencing at the post-transcriptional level, and (b) intrabody knockout of protein function at the post-translational level. Both approaches hold much promise for therapeutic applications. The pertinent question is how to choose between these alternative approaches. This commentary examines the advantages and disadvantages of these newly-emerging technology platforms. The RNAi approach is much less technically challenging than the intrabody-mediated knockout of protein function, but its major limitation is non-specificity. Although it is time-consuming and labor-intensive to generate intrabodies for specific intracellular protein targets, a much higher level of specificity can be attained. Ultimately, the choice between these strategies depend on the specific application in question, as well as on further technical advances in both technology platforms.

Keywords: downregulation, interference, intrabody, RNAi, molecuar therapeutics




This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
C. Doebis, S. Schu, J. Ladhoff, A. Busch, F. Beyer, J. Reiser, R. F. Nicosia, S. Broesel, H.-D. Volk, and M. Seifert
An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators
Cardiovasc Res, November 1, 2006; 72(2): 331 - 338.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Association of Clinical Scientists.